Archer Materials Faces Challenges as Biochip Moves to Beta Prototype and Clinical Validation Phase

Progressing from Alpha to Beta Prototype

Archer Materials Limited (ASX:AXE), a company specialising in quantum technologies and semiconductor devices, has announced a significant step forward in its Biochip program. Following the completion of its alpha prototype and the Stage 1 collaboration project with IMEC, Archer is now advancing to develop a beta prototype designed for external use and clinical validation.

The beta prototype will integrate multiple components including a silicon-based sensing chip, Archer’s proprietary functionalised layer chemistry, cartridge engineering, microfluidics, readout electronics, and software. This marks a transition from proof of concept towards productisation, with the system engineered to be robust and user-ready for external laboratories and pre-clinical trials.

Technology Platform and Manufacturing Strategy

Archer has selected silicon as the substrate for the current prototype builds, citing faster development timelines and established manufacturing pathways. While graphene remains the company’s next-generation chip platform for future performance optimisation and product expansion, the core value of Archer’s technology lies in its proprietary functionalised sensing layer and sensing architecture. This intellectual property is designed to be adaptable across different semiconductor substrates, including both silicon and graphene, which may reduce risks associated with manufacturing and commercialisation.

Dr Simon Ruffell, CEO of Archer, highlighted that the potassium sensor developed on the silicon platform demonstrated performance without compromise, alongside advantages in stability and manufacturability. This outcome supports confidence in scaling production and meeting target product requirements, as well as building a pipeline of additional Biochip applications.

Next Steps and Collaboration with IMEC

The next phase involves engineering a user-ready cartridge format, integrating readout electronics and software, and conducting shelf-life and storage stability testing. The beta prototype will enable collection of real-world performance data and user feedback, which are critical for refining the final product design and preparing for clinical trials and regulatory approval.

Archer is progressing discussions with IMEC to support fabrication scale-up, packaging, and clinical trial preparation under a Stage 2 project. This collaboration aims to facilitate the transition from prototype development to clinical validation and eventual commercial deployment.

In a broader market context, Archer’s progress reflects ongoing efforts within the quantum technology and medical diagnostics sectors to develop scalable, clinically relevant semiconductor-based sensing devices. The company’s approach of leveraging proprietary chemistry and adaptable chip architectures may offer flexibility in addressing manufacturing challenges and expanding application areas.